Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2003
09/04/2003WO2003044187A3 Emulsion compositions
09/04/2003WO2003043660A3 Composition for stabilizing hyaluronic acid
09/04/2003WO2003020265A3 Compositions comprising pectin and ascorbic acid
09/04/2003WO2003018743A3 Emu-based formulations for wound treatment
09/04/2003WO2002078600A3 γεRACK PEPTIDE COMPOSITION AND METHOD FOR PROTECTION AGAINST TISSUE DAMAGE DUE TO ISCHEMIA
09/04/2003WO2002066014A3 Cubic liquid crystalline compositions and methods for their preparation
09/04/2003WO2002060919A3 Molecules with extended half-lives, compositions and uses thereof
09/04/2003WO2002049501A3 Local regional chemotherapy and radiotherapy using in situ hydrogel
09/04/2003WO2002044228A3 Liquid dispersion polymer compositions, their preparation and their use
09/04/2003WO2002032376A3 Bile-acid conjugates for providing sustained systemic concentrations of drugs
09/04/2003WO2002020769A9 Human and mouse targeting peptides identified by phage display
09/04/2003US20030167502 Human monoclonal antibodies to dendritic cells
09/04/2003US20030167261 Small-footprint applicative query interpreter method, system and program product
09/04/2003US20030166918 Low-substituted cellulose ether powder and production process thereof
09/04/2003US20030166877 Reducing the immunogenicity of fusion proteins
09/04/2003US20030166874 Induce fibrin deposits in tumor; antitumor agents
09/04/2003US20030166868 Detecting binding; measurement; calibration
09/04/2003US20030166867 Fibrin nanoparticles and uses thereof
09/04/2003US20030166864 Controlling immunology; antiinflammatory agents
09/04/2003US20030166833 Growth factor modified protein matrices for tissue engineering
09/04/2003US20030166783 Bonding chitosan to polyoxyethylene glycol; gene therapy
09/04/2003US20030166763 Hard capsule filled with drug and polyethylene glycol
09/04/2003US20030166727 Antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity
09/04/2003US20030166709 Use of an oily suspensions, containing the active ingredient in a solid phase a N-0923 (Rotigotine) for the treatment of diseases associated with dopamine metabolism, such as Parkinson's disease
09/04/2003US20030166705 Water-based liquid preparation
09/04/2003US20030166659 Administering a sustained release drug dosage-form including >5.0% by weight ranolazine in no more than two tablets per dose to maintain ranolazine plasma levels at a >850 ng base/mL for >24 hours; methacrylic acid copolymer binder
09/04/2003US20030166631 Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
09/04/2003US20030166625 Penetration enhancing and irritation reducing systems
09/04/2003US20030166613 A macrocyclic diterpene plant extract for treating viral infections; A computer program product for storing the library information of candidate compounds
09/04/2003US20030166611 Pharmaceutical carrier for external application thereof
09/04/2003US20030166608 Polysaccharide products from durian: process for isolation and purification and their applications
09/04/2003US20030166602 A delivery vehicle low molecular weight hyaluronan ligand, glycosaminoglycan ligand for binding to antigen, with antitumor agents, or anticancer agents
09/04/2003US20030166601 Drug delivery of the nucleic acid into a target tissue or cell, comprising a core complex contains a nucleic acid and complex forming agents, fusion with cell membranes with nuclear uptake; polymeric outer shell
09/04/2003US20030166594 Comprises nucleotides/DNA on surface of microcrystalline cellulose, for oral/mucosal administration; gene therapy
09/04/2003US20030166581 Coadministered with caffeine, for prevention of seizures; for treatment of Parkinson's/Alzheimer's disease; dietetics; smoking cessation
09/04/2003US20030166566 Modified with water-soluble polyoxyethylene glycol
09/04/2003US20030166563 Vpr proteins; lentiviral pol gene expression; human and simian immunodeficiency virus (HIV/SIV) vectors
09/04/2003US20030166552 For removing viruses from samples (for protection against acquired immunodeficiency syndrome); contraceptives
09/04/2003US20030166545 Compounds and use thereof to modify transport across cell membranes
09/04/2003US20030166537 Use of a gial cell line-derived growth factor (GDNF) or a functionally active derivative or part thereof and/or an agonist which substitutes the functional activity of GDNF, and/ or a nucleic acid containing at least a nucleotide
09/04/2003US20030166532 Annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby preventing binding of the prothrombinase complex necessary for thrombus formation.
09/04/2003US20030166530 Conjugate heat shock protein-binding peptides
09/04/2003US20030166525 FSH Formulation
09/04/2003US20030166517 Galenical formulations
09/04/2003US20030166513 Dds compound and process for the preparation thereof
09/04/2003US20030166512 Protein carrier system for therapeutic oligonucleotides
09/04/2003US20030166509 Pharmaceutical compositions comprising nanoparticles containing a sustained release bioactive agent, method of making such compositions, and method of therapy using such compositions.
09/04/2003US20030166507 Water soluble paclitaxel derivatives
09/04/2003US20030166504 Therapeutic compositions and methods for treating viral infection
09/04/2003US20030166277 Targeted vaccine delivery systems
09/04/2003US20030166257 Use of Lactobacillus salivarius
09/04/2003US20030166249 PEG-urate oxidase conjugates and use thereof
09/04/2003US20030166238 Recombinant toxin fragments
09/04/2003US20030166196 Fusion proteins and polynucleotides encoding gelonin sequences
09/04/2003US20030166140 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide polyadenylation sequence all
09/04/2003US20030166057 Method and apparatus for the production of soluble MHC antigens and uses thereof
09/04/2003US20030165950 Inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in
09/04/2003US20030165853 Using peptide nucleic acids to monitor blood brain permeability and in situ gene expression in vertebrate nervous tissue
09/04/2003US20030165792 System for the controlled delivery of an active material to a dental site
09/04/2003US20030165571 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
09/04/2003US20030165569 Composition for topical substance delivery
09/04/2003US20030165568 Stabilized steroidal suspension
09/04/2003US20030165567 Administering polypeptide by injection; gene therapy
09/04/2003US20030165566 Sedative non-benzodiazepine formulations
09/04/2003US20030165565 Diltiazem; controlled release; presleep administering; cardiovascular disorders
09/04/2003US20030165555 Administering active polypeptide
09/04/2003US20030165545 Contact lenses; mixture of oil, water and surfactants
09/04/2003US20030165544 Injectable aqueous dispersions of propofol
09/04/2003US20030165516 Cytotoxic lumphocyte response; genetic engineering mutants
09/04/2003US20030165515 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
09/04/2003US20030165512 Composition of antigen and glycolipid adjuvant for sublingual administration
09/04/2003US20030165509 Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
09/04/2003US20030165478 Stabilized synthetic immunogen delivery system
09/04/2003US20030165475 Non-lethal methods for conditioning a recipient for bone marrow transplantation
09/04/2003US20030165438 Water-free ubichinon concentrate
09/04/2003US20030165436 Formulations for use in inhaler devices
09/04/2003US20030165435 Using ethanol solvent
09/04/2003US20030163931 Method for making homogeneous spray-dried soild amorphous drug dispersions utilizing modified spray-drying apparatus
09/04/2003CA2855045A1 Topical dapsone for the treatment of acne
09/04/2003CA2833470A1 Processes for preparing form 1 zd1839 polymorph
09/04/2003CA2776702A1 Topical dapsone for the treatment of acne
09/04/2003CA2740256A1 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
09/04/2003CA2702297A1 Novel crystalline forms of the anti-cancer compound zd1839
09/04/2003CA2662899A1 Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
09/04/2003CA2503094A1 Therapeutic methods for acute myeloid leukemia
09/04/2003CA2477607A1 Substituted hydroxyethylamines
09/04/2003CA2477350A1 Novel crystalline forms of the anti-cancer compound zd1839
09/04/2003CA2477281A1 Method of using modified oligonucleotides for hepatic delivery
09/04/2003CA2477105A1 Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
09/04/2003CA2477049A1 Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
09/04/2003CA2477044A1 Ophthalmic formulation with gum system
09/04/2003CA2477038A1 Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
09/04/2003CA2476972A1 Pharmaceutical dosage form and method for the production thereof
09/04/2003CA2476769A1 Carbohydrate-modified polymers, compositions and uses related thereto
09/04/2003CA2476589A1 Compositions for delivery of therapeutics and other materials, and methods of making and using the same
09/04/2003CA2476171A1 Pharmaceutical dosage forms comprising tablet core having a tensile strength below 38 n/sqcm and a coating to protect the soft core
09/04/2003CA2476170A1 Fast disintegrating tablets
09/04/2003CA2475253A1 Therapeutical polyanhydride compounds for drug delivery
09/04/2003CA2475039A1 Macromolecular conjugates and processes for preparing same
09/04/2003CA2473625A1 Oral trimethobenzamide formulations and methods
1 ... 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 ... 1712